CD274 and non-small cell lung carcinoma: One phase I trial with a specific expansion cohort for NSCLC patients (n = 26) evaluated the safety and clinical efficacy of ciforadenant as monotherapy or in combination with atezolizumab (PD-L1 inhibitor) [98].